ArticleHaematologica2014
STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression.
Article in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Dual action of pimozide through lysosome disruption and inhibition of STATs induces apoptosis in chronic lymphocytic leukemia (CLL).Blood advances · 2026Article
- ALK-negative Anaplastic Large Cell Lymphoma Presenting as Back Pain.Journal of community hospital internal medicine perspectives · 2026Article
- Dimeric natural product panepocyclinol A inhibits STAT3Acta pharmaceutica Sinica. B · 2025Article
- Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024Review
- Evaluation of Signal Transducer and Activator of Transcription 3 (STAT-3) Protein Expression in Non-Hodgkin Lymphoma Cases in Hospital USM.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.Haematologica · 2021Article
- Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.Nature communications · 2021Article
- Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.Haematologica · 2021Article
- STAT3 Activation and Oncogenesis in Lymphoma.Cancers · 2019Review
- Review
- Genomics of LGL leukemia and select other rare leukemia/lymphomas.Best practice & research. Clinical haematology · 2019Review
- Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.Journal of translational medicine · 2018Article
- Nucleus, Mitochondrion, or Reticulum? STAT3 à La Carte.International journal of molecular sciences · 2018Review
- Mutations in the signal transducer and activator of transcription family of genes in cancer.Cancer science · 2018Review
- Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.Blood advances · 2018Article
- Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.Oncotarget · 2017Article
- Article
- The heterogeneous landscape of ALK negative ALCL.Oncotarget · 2017Review
Corrections and comments
- Comment on
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.